Kiniksa Pharmaceuticals Ltd (KNSA) — Cash Flow-to-Debt Ratio
Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow-to-Debt Ratio of 0.23x as of March 2026, meaning its operating cash flow of $50.20 Million could theoretically repay 0% of its total liabilities ($219.59 Million) in one year. See Kiniksa Pharmaceuticals Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kiniksa Pharmaceuticals Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Kiniksa Pharmaceuticals Ltd across 10 annual periods. Also explore KNSA net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Kiniksa Pharmaceuticals Ltd (2016–2025)
Year-by-year debt coverage analysis for Kiniksa Pharmaceuticals Ltd. For market capitalisation and broader financial context, see market value of Kiniksa Pharmaceuticals Ltd.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.13x | $25.69 Million | $196.03 Million | ▼ -27.5% |
| 2024 | 0.18x | $25.69 Million | $142.12 Million | ▲ +18.9% |
| 2023 | 0.15x | $13.30 Million | $87.48 Million | ▲ +66.3% |
| 2022 | 0.09x | $5.81 Million | $63.52 Million | ▲ +103.5% |
| 2021 | -2.64x | $-126.30 Million | $47.76 Million | ▲ +27.3% |
| 2020 | -3.64x | $-136.53 Million | $37.53 Million | ▲ +33.1% |
| 2019 | -5.44x | $-158.37 Million | $29.11 Million | ▼ -186.7% |
| 2018 | -1.90x | $-81.01 Million | $42.70 Million | ▼ -418.4% |
| 2017 | -0.37x | $-50.22 Million | $137.20 Million | ▼ -37.6% |
| 2016 | -0.27x | $-21.87 Million | $82.20 Million | — |